Browsing Tag
gene therapy
66 posts
MeiraGTx signs $475m ophthalmology gene therapy collaboration with Eli Lilly
MeiraGTx Holdings plc signed a USD 475 million gene therapy deal with Eli Lilly and Company to develop AAV-AIPL1 and apply riboswitch tech in ophthalmology.
uniQure moves closer to FDA approval as AMT-130 gene therapy shows progress for Huntington’s disease
Find out how uniQure’s AMT-130 regulatory path for Huntington’s disease is evolving after the FDA’s latest feedback on its data sufficiency.
Breakthrough hope: Benitec Biopharma’s BB-301 delivers promising results in rare muscular dystrophy trial
Find out how Benitec Biopharma’s BB-301 gene therapy is showing early success in restoring swallowing function for OPMD patients.
Can Lilly’s milestone-heavy deal for Adverum reshape how Big Pharma acquires gene therapy platforms?
Lilly’s $12.47-per-share buyout of Adverum Biotechnologies puts milestone CVRs at the center of biotech M&A. But can this deal model truly balance risk and reward?
Lilly’s $262m Adverum Biotechnologies buyout marks a major push into ocular gene therapy
Find out how Eli Lilly’s $262 million Adverum Biotechnologies buyout is advancing gene-therapy innovation in vision care!
Genenta Science partners with Anemocyte to unlock scalable LVV plasmid DNA supply for global cell and gene therapy developers
Find out how Genenta Science and Anemocyte are scaling off-the-shelf LVV plasmid DNA to revolutionize global gene and cell therapy manufacturing.
Cabaletta Bio’s rese-cel CAR-T data at ESGCT 2025 reveal biologic activity without preconditioning in autoimmune disease
Cabaletta Bio’s ESGCT 2025 rese-cel data show early CAR-T activity without chemotherapy preconditioning — see how this could redefine autoimmune therapy.
Oxford Biomedica (LSE: OXB) expands US manufacturing base with Durham viral vector facility buy
Find out how Oxford Biomedica’s new US viral vector facility strengthens its CDMO leadership and growth trajectory.
Base editing 101: Is precision gene editing safer than CRISPR‑Cas9 for therapeutic use?
Is base editing safer than CRISPR? See how Beam, Verve, and Prime are using non-cutting gene editing to raise the bar for precision and clinical safety.
Base editing vs CRISPR: Why Beam Therapeutics’ sickle cell therapy may quietly become a blockbuster
Weeks after Beam’s BEAM-101 earned RMAT status, here’s why base editing may still reshape sickle cell therapy—and what investors should watch next.